Author(s): Tan S, Schubert D, Maher P
Extensive nerve cell death occurs during the development of the central nervous system as well as in episodes of trauma and in neurodegenerative disease. The mechanistic details of how these cells die are poorly understood. Here we describe a unique oxidative stress-induced programmed cell death pathway called oxytosis, and outline pharmacological approaches which interfere with its execution. Oxidative glutamate toxicity, in which exogenous glutamate inhibits cystine uptake through the cystine/glutamate antiporter leading to a depletion of glutathione, is used as an example of oxytosis. It is shown that there is a sequential requirement for de novo macromolecular synthesis, lipoxygenase activation, reactive oxygen species production, and the opening of cGMP-gated channels which allow the influx of extracellular calcium. The translation initiation factor elF2alpha plays a central role in this pathway by regulating the levels of glutathione. Finally, examples are given in which the reduction in glutathione, the production of reactive oxygen species, and calcium influx can be experimentally manipulated to prevent cell death. Data are reviewed which suggest that oxytosis may be involved in nerve cell death associated with nervous system trauma and disease.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/11895126
Author(s): Fang MC, Cutler DM, Rosen AB
Author(s): Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, et al.
Author(s): Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, et al.
Author(s): Lapchak PA
Author(s): Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, et al.
Author(s): Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, et al.
Author(s): Verstraete M
Author(s): [No authors listed]
Author(s): Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, et al.
Author(s): Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, et al.
Author(s): Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M
Author(s): Schubert D, Piasecki D
Author(s): Liu Y, Dargusch R, Maher P, Schubert D
Author(s): Lapchak PA, McKim JM Jr
Author(s): Valera E, Dargusch R, Maher PA, Schubert D
Author(s): Jayaraj RL, Tamilselvam K, Manivasagam T, Elangovan N
Author(s): Lapchak PA, Schubert DR, Maher PA
Author(s): Panzhinskiy E, Hua Y, Lapchak PA, Topchiy E, Lehmann TE, et al.
Author(s): Narumoto O, Matsuo Y, Sakaguchi M, Shoji S, Yamashita N, et al.
Author(s): Elgebaly MM, Ogbi S, Li W, Mezzetti EM, Prakash R, et al.
Author(s): Moskowitz MA, Lo EH, Iadecola C
Author(s): Lapchak PA
Author(s): Lapchak PA
Author(s): Liu Y, Dargusch R, Maher P, Schubert D
Author(s): Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, et al.
Author(s): Chandler WL, Trimble SL, Loo SC, Mornin D
Author(s): Liot G, Benchenane K, Léveillé F, López-Atalaya JP, Fernández-Monreal M, et al.
Author(s): Fisher M1; Stroke Therapy Academic Industry Roundtable
Author(s): Stroke Therapy Academic Industry Roundtable (STAIR)1
Author(s): Spengos K, Behrens S, Daffertshofer M, Dempfle CE, Hennerici M
Author(s): Schulz KF, Altman DG, Moher D; CONSORT Group
Author(s): Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, et al.
Author(s): Lapchak PA
Author(s): Ebinger M, Winter B , Wendt M, Weber JE, Waldschmidt C, et al.